Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...

Plump was appointed chief medical and scientific officer at Takeda in 2015, stepping up to the role of president three years later. Andy Plump, credited with a 'soup-to-nuts' overhaul of Takeda's R&D ...

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual ...

The National Commission into the Regulation of AI in Healthcare has delivered its keenly anticipated report, which gives ...

Right after reporting encouraging data with its Dravet syndrome gene therapy, Encoded Therapeutics has raised an impressive ...

There's no underplaying the seriousness of chronic obstructive pulmonary disease (COPD), the third leading cause of death worldwide, but a new study suggests laughter may be the right response.

Some pharmacists in England can now prescribe medicines for acne, migraines, scabies, ear infections, and rhinitis in a major expansion of the Pharmacy First scheme first introduced in 2024. The five ...

Susan Marlin, chief executive of Clinical Trials Ontario, and Invest Ontario's life sciences lead Garrett Tone, say changes ...

Europe is rapidly becoming a hub for next-generation CNS biomarker innovation, with advances in blood-based, digital and ...

The FDA has just started a priority review of Roche's anti-IL-6 inhibitor Enspryng (satralizumab) for MOGAD – myelin ...

Bayer has won FDA approval for oral HER2 inhibitor Hyrnuo as a first-line treatment for advanced HER2-mutant non-small cell ...

Now We Must", this year emphasised the urgency and possibility of ending malaria with existing tools, progressive science, ...